John Wilkerson , 2025-04-21 08:30:00
When should six drugs count as one?
That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have major ramifications for the Medicare drug price negotiation program, a signature accomplishment of former President Biden that President Trump has also embraced.
Novo argues that the federal government should be forced to negotiate the price for six of its insulin products separately, even though they all contain the same active ingredient. The government says that the law allows it to lump all these products together.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
